PMID- 10848779
OWN - NLM
STAT- MEDLINE
DCOM- 20000712
LR  - 20190705
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 109
IP  - 1
DP  - 2000 Apr
TI  - Amplification of cyclin D1 gene in multiple myeloma: clinical and prognostic 
      relevance.
PG  - 30-8
AB  - Approximately 30% of myeloma patients express cyclin D1 RNA and protein. The low 
      incidence of translocation t(11; 14) detected by conventional cytogenetics 
      suggests that the up-regulation of cyclin D1 protein might result from other 
      mechanisms as well as from gene amplification. Therefore, the frequency and the 
      clinical and prognostic implications of cyclin D1 amplification were examined. We 
      highly purified myeloma cells from bone marrow by magnetic cell sorting and 
      analysed 50 myelomas by fluorescence in situ hybridization (FISH) using probes 
      specific for cyclin D1 and 20 samples by immunoblotting to detect cyclin D1 
      expression. The amplification of cyclin D1 gene was found in 19 of 50 analysed 
      patients and was associated with expression of cyclin D1 protein. The 
      amplification correlated significantly with the bone marrow infiltration, plasma 
      cell morphology and labelling index as well as serum beta2-microglobulin, 
      C-reactive protein (CRP) and creatinine levels. In univariate analysis, the 
      amplification of the cyclin D1 gene was a significantly unfavourable parameter 
      with regard to overall survival (P = 0.0064) and progression-free survival (P = 
      0. 0005). In multivariate analysis, cyclin D1 amplification and serum 
      beta2-microglobulin were independent and well-suited parameters for predicting 
      survival. The detection of cyclin D1 amplification seems to be of promising 
      prognostic value in multiple myeloma.
FAU - Hoechtlen-Vollmar, W
AU  - Hoechtlen-Vollmar W
AD  - Institute of Clinical Chemistry, Ludwig Maximilians Universitaet Muenchen, 
      Grosshadern, Munich, Germany. Lomerz@med2.med.uni-muenchen.de
FAU - Menzel, G
AU  - Menzel G
FAU - Bartl, R
AU  - Bartl R
FAU - Lamerz, R
AU  - Lamerz R
FAU - Wick, M
AU  - Wick M
FAU - Seidel, D
AU  - Seidel D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Biomarkers)
RN  - 0 (beta 2-Microglobulin)
RN  - 136601-57-5 (Cyclin D1)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Analysis of Variance
MH  - Biomarkers/blood
MH  - Case-Control Studies
MH  - Child
MH  - Child, Preschool
MH  - Cyclin D1/analysis/*metabolism
MH  - Disease-Free Survival
MH  - Gene Amplification
MH  - *Genes, bcl-1
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Infant
MH  - Infant, Newborn
MH  - Middle Aged
MH  - Multiple Myeloma/*genetics
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - beta 2-Microglobulin/metabolism
EDAT- 2000/06/10 09:00
MHDA- 2000/07/15 11:00
CRDT- 2000/06/10 09:00
PHST- 2000/06/10 09:00 [pubmed]
PHST- 2000/07/15 11:00 [medline]
PHST- 2000/06/10 09:00 [entrez]
AID - bjh2007 [pii]
AID - 10.1046/j.1365-2141.2000.02007.x [doi]
PST - ppublish
SO  - Br J Haematol. 2000 Apr;109(1):30-8. doi: 10.1046/j.1365-2141.2000.02007.x.